OncoGeneX Technologies has announced that the first patient has been treated in a Phase II clinical trial of OGX-011 in combination with gemcitabine and cisplatin in chemotherapy naive patients with advanced non-small cell lung cancer.
Drug Criteria & Outcomes: In The Pipeline
Drug Criteria & Outcomes
- OncoGeneX Technologies has announced that the first patient has been treated in a Phase II clinical trial of OGX-011 in combination with gemcitabine and cisplatin in chemotherapy naive patients with advanced non-small cell lung cancer.
- Halozyme Therapeutics has received clearance from the FDA for its Chemophase Investigational New Drug (IND) application. The initial clinical protocol under this IND is a Phase I study designed to evaluate a single intravesical administration of Chemophase along with mitomycin in patients with superficial bladder cancer.
- Genmab A/S announced that it has initiated a Phase II study with HuMax-CD20 to treat patients with active rheumatoid arthritis who have failed one treatment with one or more disease modifying anti-rheumatic drugs.
- GenomiX has announced that the first patient has been enrolled in a Phase II/III clinical trial of Troxatyl, a novel anticancer drug candidate for treatment of acute myelogenous leukemia.
- Millennium Pharmaceuticals has initiated of a randomized, double-blind, placebo-controlled Phase II clinical trial of MLN1202 in patients at risk for atherosclerotic cardiovascular disease.
- MediGene AG has initiated a Phase II clinical trial of drug candidate EndoTAG(TM)-1 for the treatment of advanced pancreatic cancer.
- AEterna Zentaris has completed enrollment for a Phase II trial with ozarelix (D-63153) in hormone-dependent prostate cancer.
- Cadence Pharmaceuticals has announced that investigators have initiated enrollment in its pivotal Phase III trial of CPI-226 for the prevention of catheter-related infections.
- MIGENIX has announced the initiation of United States enrollment in a multinational Phase III clinical study with MX-226 (also known as CPI-226), a compound in development for the prevention of catheter-related infections.
- BioCryst Pharmaceuticals has announced that one of its investigators at the University of Texas M.D. Anderson Cancer Center has initiated a Phase II trial of oral forodesine hydrochloride (Fodosine), a transition-state analog inhibitor of purine nucleoside phosphorylase. The trial is designed to evaluate the efficacy and safety of forodesine hydrochloride in patients with advanced, fludarabine-refractory chronic lymphocytic leukemia.
- Novartis announced that the FDA has granted priority review to letrozole tablets (Femara) in the adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.